[Intestinal microbiom modulates the response to antitumor immunotherapy]

Area of Science:

• Oncology
• Immunology
• Microbiology

Background:

• The intestinal microbiota plays a crucial role in human bodily processes.
• Emerging evidence links gut microbiota composition to the success of cancer therapies, including chemotherapy and immunotherapy.
• The gut microbiome is recognized as a potential target for enhancing antitumor therapy effectiveness and reducing toxicity.

Purpose of the Study:

• To review current research on the relationship between the gut microbiome and the efficacy of immune checkpoint inhibitors in cancer treatment.
• To highlight the mechanisms through which the gut microbiota may influence antitumor responses.
• To identify discrepancies in existing data for future research directions.

Main Methods:

• Literature review of studies investigating the gut microbiome's role in cancer immunotherapy.
• Analysis of proposed mechanisms, including immunomodulation and drug metabolism.
• Synthesis of findings on the predictive value of the gut microbiome for immunotherapy success.

Main Results:

• The gut microbiome influences antitumor efficacy, particularly with immune checkpoint inhibitors.
• Mechanisms involve general immunomodulation and specific immune cell responses to microbial and tumor antigens.
• The gut microbiome affects drug metabolism and degradation, impacting treatment outcomes.
• Gut microbiome composition is increasingly viewed as a predictor of immunotherapy success.

Conclusions:

• The gut microbiome is a critical factor in antitumor immune responses and immunotherapy outcomes.
• Understanding the gut microbiome offers potential for optimizing cancer treatment strategies and reducing side effects.
• Further research is essential to resolve data discrepancies and fully leverage the gut microbiome in oncology.